Analysts Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $20.83

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have received an average recommendation of "Buy" from the eight ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $20.83.

Several brokerages recently issued reports on ALT. HC Wainwright reiterated a "buy" rating and issued a $12.00 price target on shares of Altimmune in a research note on Wednesday. Stifel Nicolaus started coverage on shares of Altimmune in a research note on Wednesday, January 8th. They set a "buy" rating and a $18.00 target price for the company. Finally, UBS Group started coverage on shares of Altimmune in a report on Tuesday, November 12th. They set a "buy" rating and a $26.00 target price for the company.

Altimmune Stock Down 3.6 %

Shares of ALT traded down $0.25 during trading hours on Friday, reaching $6.66. 1,440,025 shares of the company traded hands, compared to its average volume of 2,126,872. Altimmune has a 12 month low of $5.28 and a 12 month high of $14.84. The company has a market capitalization of $473.69 million, a price-to-earnings ratio of -4.30 and a beta of 0.19. The company's fifty day moving average price is $7.59 and its two-hundred day moving average price is $7.17.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million during the quarter. During the same quarter last year, the business earned ($0.39) earnings per share. On average, analysts expect that Altimmune will post -1.35 EPS for the current year.

Institutional Investors Weigh In On Altimmune

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALT. Larson Financial Group LLC bought a new stake in Altimmune during the 3rd quarter valued at approximately $31,000. SBI Securities Co. Ltd. bought a new stake in shares of Altimmune during the fourth quarter valued at approximately $45,000. Cullen Frost Bankers Inc. bought a new stake in shares of Altimmune during the fourth quarter valued at approximately $72,000. 180 Wealth Advisors LLC purchased a new position in shares of Altimmune in the fourth quarter worth $78,000. Finally, Raymond James Financial Inc. bought a new position in shares of Altimmune during the fourth quarter worth $88,000. Institutional investors own 78.05% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.